Pharmacokinetics, lymph node uptake, and mechanistic PK model of near-infrared dye-labeled bevacizumab after IV and SC administration in mice

AAPS Journal

Volumn 14, Issue 2, 2012, Pages 252-261

  Wu, Fang ^a   Tamhane, Mitalee ^a   Morris, Marilyn E ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Bevacizumab; Bioavailability; Fluorescence imaging; Lymphatic absorption; Pharmacokinetics

Indexed keywords

BEVACIZUMAB; DYE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; AXILLARY LYMPH NODE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG LYMPH LEVEL; DRUG UPTAKE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE IMAGING; GEL PERMEATION CHROMATOGRAPHY; LYMPH NODE; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PLASMA CLEARANCE; PLASMA CONCENTRATION-TIME CURVE; POLYACRYLAMIDE GEL ELECTROPHORESIS; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; FLUORESCENT DYES; HUMANS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; LYMPH NODES; MALE; MICE; MODELS, BIOLOGICAL; SPECTROSCOPY, NEAR-INFRARED;

EID: 84860773421     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-012-9342-9     Document Type: Article

References (30)

1. Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, Krummen L, Winkler M, Ferrara N. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 1997;57 (20):4593-9. (Pubitemid 27441066)
2. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004;3(5):391-400. (Pubitemid 38618122)
3. Cohen MH, Gootenberg J, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab (Avastin(R)) plus carboplatin and paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist. 2007;12(6):713-8. (Pubitemid 47036205)
4. Cohen MH, Shen YL, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist. 2009;14(11):1131-8.
5. Wang W, Wang EQ, Balthasar JP. Monoclonal antibody phar-macokinetics and pharmacodynamics. Clin Pharmacol Ther. 2008;84(5):548-58.
6. Supersaxo A, Hein WR, Steffen H. Effect of molecular weight on the lymphatic absorption of water-soluble compounds following subcutaneous administration. Pharm Res. 1990;7(2):167-9. (Pubitemid 20208069)
7. Kagan L, Gershkovich P, Mendelman A, Amsili S, Ezov N, Hoffman A. The role of the lymphatic system in subcutaneous absorption of macromolecules in the rat model. Eur J Pharm Biopharm. 2007;67(3):759-65. (Pubitemid 47576609)
8. Kojima K, Takahashi T, Nakanishi Y. Lymphatic transport of recombinant human tumor necrosis factor in rats. J Pharmaco-biodyn. 1988;11(10):700-6. (Pubitemid 18268044)
9. Chang SK, Rizvi I, Solban N, Hasan T. In vivo optical molecular imaging of vascular endothelial growth factor for monitoring cancer treatment. Clin Cancer Res. 2008;14(13):4146-53.
10. McLennan DN, Porter CJ, Edwards GA, Brumm M, Martin SW, Charman SA. Pharmacokinetic model to describe the lymphatic absorption of r-metHu-leptin after subcutaneous injection to sheep. Pharm Res. 2003;20(8):1156-62. (Pubitemid 36951839)
11. Radwanski E, Chakraborty A, Van Wart S, Huhn RD, Cutler DL, Affrime MB, et al. Pharmacokinetics and leukocyte responses of recombinant human interleukin-10. Pharm Res. 1998;15(12):1895-901. (Pubitemid 29034840)
12. Gearing AJH, Thorpe SJ, Miller K, Mangan M, Varley PG, Dudgeon T, et al. Selective cleavage of human IgG by the matrix metalloproteinases, matrilysin and stromelysin. Immunol Lett. 2002;81(1):41-8. doi:10.1016/S0165-2478(01)00333-9. (Pubitemid 34159039)
13. Phelps MA, Foraker AB, Gao W, Dalton JT, Swaan PW. A novel rhodamine-riboflavin conjugate probe exhibits distinctfluorescence resonance energy transfer that enables riboflavin trafficking and subcellular localization studies. Mol Pharm. 2004;1(4):257-66.
14. Wu F, Wuensch SA, Azadniv M, Ebrahimkhani MR, Crispe IN. Galactosylated LDL nanoparticles: a novel targeting delivery system to deliver antigen to macrophages and enhance antigen specific T cell responses. Mol Pharm. 2009;6(5):1506-17.
15. Xu G, Yong KT, Roy I, Mahajan SD, Ding H, Schwartz SA, et al. Bioconjugated quantum rods as targeted probes for efficient transmigration across an in vitro blood-brain barrier. Bioconjug Chem. 2008;19(6):1179-85. (Pubitemid 351877059)
16. Yong KT, Ding H, Roy I, Law WC, Bergey EJ, Maitra A, et al. Imaging pancreatic cancer using bioconjugated InP quantum dots. ACS Nano. 2009;3(3):502-10.
17. Chernomordik V, Hassan M, Lee SB, Zielinski R, Gandjbakhche A, Capala J. Quantitative analysis of Her2 receptor expression in vivo by near-infrared optical imaging. Mol Imaging. 2010;9(4):192-200.
18. Lee SB, Hassan M, Fisher R, Chertov O, Chernomordik V, Kramer-Marek G, et al. Affibody molecules for in vivo characterization of HER2-positive tumors by near-infrared imaging. Clin Cancer Res. 2008;14(12):3840-9.
19. Biffi S, Garrovo C, Macor P, Tripodo C, Zorzet S, Secco E, et al. In vivo biodistribution and lifetime analysis of cy5.5-conjugated rituximab in mice bearing lymphoid tumor xenograft using time-domain near-infrared optical imaging. Mol Imaging. 2008;7(6):272-82.
20. Ding H, Yong KT, Law WC, Roy I, Hu R, Wu F, et al. Non-invasive tumor detection in small animals using novel functional Pluronic nanomicelles conjugated with anti-mesothelin antibody. Nanoscale. 2011;3(4):1813-22.
21. Zhu J, Yong KT, Roy I, Hu R, Ding H, Zhao L, et al. Additive controlled synthesis of gold nanorods (GNRs) for two-photon luminescence imaging of cancer cells. Nanotechnology. 2010;21 (28):285106.
22. Kopwitthaya A, Yong KT, Hu R, Roy I, Ding H, Vathy LA, et al. Biocompatible PEGylated gold nanorods as colored contrast agents for targeted in vivo cancer applications. Nanotechnology. 2010;21(31):315101.
23. Licha K, Debus N, Emig-Vollmer S, Hofmann B, Hasbach M, Stibenz D, et al. Optical molecular imaging of lymph nodes using a targeted vascular contrast agent. J Biomed Opt. 2005;10 (4):41205.
24. Lin YS, Nguyen C, Mendoza JL, Escandon E, Fei D, Meng YG, et al. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. J Pharmacol Exp Ther. 1999;288 (1):371-8. (Pubitemid 29113511)
25. Shah DK, Veith J, Bernacki RJ, Balthasar JP. Evaluation of combined bevacizumab and intraperitoneal carboplatin or pacli-taxel therapy in a mouse model of ovarian cancer. Cancer Chemother Pharmacol. 2011;68(4):951-8.
26. Bhansali SG, Balu-Iyer SV, Morris ME. Influence of route of administration and liposomal encapsulation on blood and lymph node exposure to the protein VEGF-C156S. J Pharm Sci. 2012;101(2):852-9.
27. Porter CJ, Charman SA. Lymphatic transport of proteins after subcutaneous administration. J Pharm Sci. 2000;89(3):297-310. (Pubitemid 30152431)
28. Engeset A. The route of peripheral lymph to the blood stream; an X-ray study of the barrier theory. J Anat. 1959;93 (1):96-100.
29. Kubik S. Anatomy of the lymphatic system. In: Foldi M, Foldi E, Kubik S, editors. Textbook of lymphology. San Francisco: Elsevier GmbH; 2003. p. 1-166.
30. Wu F, Bhansali SG, Tamhane M, Kumar R, Vathy LA, Ding H, et al. Noninvasive real-time fluorescence imaging of the lymphatic uptake of BSA-IRDye 680 conjugate administered subcutaneously in mice. J Pharm Sci. 2012. doi:10.1002/jps.23058.